Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

- Record EPS of $0.73, up 192% from third quarter 2007 - New business awards of $212 million, up 21% from third quarter 2007 - Total business authorizations of $1 billion at Sept. 30, 2008, up 16%

from Dec. 31, 2007

CINCINNATI, Nov. 4 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today reported record net income of $11.0 million or $0.73 per diluted share for its third quarter ended Sept. 30, 2008, compared to net income of $3.8 million, or $0.25 per diluted share for the third quarter ended Sept. 30, 2007. Net income for the third quarter of 2007 included a charge for the write-off of deferred financing costs related to the Company's term debt, which was paid off in the third quarter of 2007. The charges totaled $4.2 million or $0.18 per diluted share. Excluding the effect of this item, earnings per share for third quarter 2007 were $0.43 on a diluted basis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

Net service revenues for the quarter ended Sept. 30, 2008, were $124.8 million, an increase of 25 percent over the same period in 2007. Net service revenues from the June 2, 2008, acquisition of DecisionLine Clinical Research Corporation accounted for approximately 6 percent of the growth in third quarter 2008 net service revenues. The top five customers based on net service revenues accounted for 24 percent of net service revenues for both the third quarter of 2008 and the third quarter 2007.

New business awards for the quarter totaled a record $212 million, an increase of 21 percent over the same pe
'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... million, seven-year contract with the National Institute of Allergy ... of Health, to conduct preclinical development of potential therapies ... development of drugs to treat HIV and AIDS and ... as well as microbicides for preventing sexual transmission of ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... INDIANAPOLIS , and WALTHAM, Mass. , June 15, 2010 ... Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) ... to test the superiority of BYDUREON™ (exenatide extended-release for injectable suspension), an investigational ... , , , ...
... , June 15 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... of conference calls focused on the drugs in Isis, development pipeline.  The last ... held on Thursday, June 17, 2010 at 12:00 p.m. ET ... site. , , , ...
... June 15, 2010 Pieris AG,announced today the initiation of a ... anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of the compound,s safety ... , the trial is underway and patients from the first cohort have ... ...
Cached Biology Technology:DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 2DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 4DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 5DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 6DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 7DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 8DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 9Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 2Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 3Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2
(Date:7/24/2014)... Singapore have developed Asia,s first genetic test for identifying ... the cornea called corneal stromal dystrophy which can lead ... the POLARIS TGFBI (Transforming Growth Factor beta Induced) test, ... diagnosis and management of patients with corneal stromal dystrophies. ... mutation who may also be at risk of developing ...
(Date:7/23/2014)... found that early reading skill might positively affect later ... Development , was conducted by researchers at the University ... is an ability that can be improved, our findings ... Ritchie, research fellow in psychology at the University of ... problems might aid not only the growth of literacy, ...
(Date:7/23/2014)... Carolina State University shows that urban "heat islands" are ... One factor is that researchers have found warmer temperatures ... scale insect a significant tree pest by ... more adult gloomy scales on urban trees. , "We,d ... gloomy scale in cities, and now we know why," ...
Breaking Biology News(10 mins):Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3Stronger early reading skills predict higher intelligence later 2Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3
... poisonous ― but it might be used as an ... Tel Aviv University researcher claims. Prof. ... Sciences is investigating new ways for developing a novel ... of scorpions. These compounds have gone through millions of ...
... Bridget (Birgitta) of Sweden that has been kept in a ... study conducted at Uppsala University reveals that the two skulls, ... (Katarina), is not from maternally related individuals. Furthermore, dating show ... Bridget and Catherine lived. The findings are published in the ...
... will greatly benefit the U.S., say scientists in an ... of America (ESA), the nation,s largest organization of ecological ... and economic benefits of biofuel production, U.S. policies need ... ecosystems. In the report, scientists Virginia Dale, Keith ...
Cached Biology News:Pinch away the pain 2Pinch away the pain 3The putative skull of St. Bridget can be questioned 2Beyond the corn field: Balancing fuel, food and biodiversity 2
...
... quantitation kit is used to quantitate double-stranded DNA ... RNA or protein. With this kit, DNA is ... detected with a VersaFluor or other fluorometer. The ... ng per ml to 5 micrograms per ml ...
... colony stimulating factors for assays of mouse ... and fetal liver. Suitable for the ... CFU-GEMM when added to methylcellulose at a ... erythropoietin. Will also support growth of ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Biology Products: